Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma

Summary

This is Phase II trial of nivolumab plus axitinib for patients with unresectable stage III or IV melanoma who have progressed on prior anti-PD1 therapy with or without concomitant anti-CTLA4 therapy. Patients will receive treatment with nivolumab 480 mg intravenously every 4 weeks and axitinib 5 mg twice daily by mouth. Patients may continue both agents for up to two years if they do not experience disease progression or dose-limiting toxicities.

Timeline

Start

2020-12-18

Primary completion

2024-04-15

Completion

2025-04-12

Drugs

Indications